10 results about "Antimalarial medication" patented technology

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

This invention provides the application of Pulsatilla saponin B4 in the preparation of antimalarial drugs, which can significantly improve weight loss, peripheral blood parasitemia, and survival rate in mice infected with lethal Plasmodium. Its mechanism of action is not to directly kill Plasmodium, but to regulate the host immune system, including activating T / B cell immune responses, upregulating pro-inflammatory factors and interferon signaling pathways, and downregulating Arg1 expression. At the same time, Pulsatilla saponin B4 can alleviate immunopathological damage to organs such as the spleen and liver, restore the homeostasis of the spleen's immune microenvironment, and protect the normal structure of tissues. As a natural product, this compound has the characteristics of multiple targets and low toxicity, and has the dual advantages of anti-infection and immune homeostasis regulation, showing good prospects for clinical application and translation.

Disclosed herein are methods and compositions for treating and / or preventing Plasmodium falciparum malaria by administering a compound that mimics the binding of anti-Plasmodium falciparum Glutamic Acid Rich Protein (PfGARP).

The invention discloses application of a naturally-sourced small molecule compound and a pharmaceutical composition thereof in preparation of antimalarial drugs, and belongs to the technical field of biological medicines. The small molecule compound is PHPP, the CAS number of the small molecule compound is 252205-23-5, and the structure of the small molecule compound is shown in the specification. According to the invention, the small molecule compound PHPP, which is a specific monomer component, is screened from natural products for the first time and is proved to have remarkable anti-malarial activity, and the cognitive blank of the anti-malarial application of the small molecule compound is filled up; the compound not only has an excellent in-vitro anti-malarial effect, but also has no obvious cytotoxicity under an effective concentration and is high in safety; more importantly, when the compound is combined with artemisinin, a remarkable synergistic effect can be generated, a brand new solution is provided for solving the problem of severe artemisinin drug resistance, and candidate lead compounds and combination schemes with wide prospects are provided for developing new-generation antimalarial drugs.

The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.

This invention belongs to the field of drug synthesis and relates to a highly efficient hydrogen-borrowing reaction strategy for the preparation of ferroquinone (FQ). This strategy uses commercially available ferrocene as a starting material, constructs the key precursor ferrocene diol through two-step conversion, and then proceeds through two hydrogen-borrowing reactions, successfully inventing a highly efficient method for the preparation of FQ in four steps with an overall yield of 69%. Compared with previously reported routes, this method shortens the reaction steps, increases the reaction yield (the overall yield of the existing ferroquinone synthesis route in the background art is 39%), is simpler to operate, and is environmentally friendly (the only byproduct in the hydrogen-borrowing reaction is water). It can be widely used, laying a solid foundation for in-depth pharmacological and physiological activity research of FQ, and providing a novel and universal strategy for developing new scaffolds for candidate drug molecules with high activity and high selectivity of FQ derivatives.

The invention shows that a P. falciparum-specific interaction between a PfEMP1 adhesin and the endothelial receptor CD36 modulates sporozoite infectivity. Using a synthetic peptide to leverage this interaction, a robust high-throughput screening method has been developed to identify next-generation prophylactics against this deadly malaria parasite. The synthetic peptide is also used as a prophylactic medicament to prevent P. falciparum infection in a subject.

This invention relates to a 6- O -L-arabinopyranosyl- β The preparation of β-D-glucopyranoside and its application in the preparation of antimalarial products belong to the field of traditional Chinese medicine and natural drug pharmaceuticals. Compound 6- of this invention... O -L-arabinopyranosyl- β This invention relates to an antimalarial drug with β-D-glucopyranoside as the active ingredient. It expands the application of aromatic disaccharide compounds 6- from *Hydrangea macrophylla*. O -L-arabinopyranosyl- β The medicinal value of D-glucopyranoside.

The application discloses an AKK and / or outer membrane vesicle thereof induced macrophage polarization method and application thereof in preparation of a medicine for promoting phagocytosis of infected red blood cells by macrophages, and belongs to the technical field of biological medicines. It is found by the application that macrophages are subjected to M1 polarization phenomenon after being induced by AKK bacteria or OMVs thereof. The macrophages subjected to M1 polarization produce proinflammatory factors, and phagocytose more red blood cells infected by Plasmodium. In the absence of existing anti-malaria medicines, compared with macrophages not subjected to M1 polarization, the macrophages subjected to M1 polarization only by AKK bacteria or AKK-OMVs can phagocytose more red blood cells infected by Plasmodium, effectively avoiding the resistance of Plasmodium to anti-malaria medicines caused by long-term use of the anti-malaria medicines, and providing a new scheme for clinical malaria treatment.

The invention discloses an application of an anti-malarial drug primaquine phosphate in preparation of drugs for treating BCR-ABL positive leukemia and breast cancer and a drug combination composition, and discovers that the anti-malarial drug primaquine phosphate has obvious effects of resisting BCR-ABL + leukemia and breast cancer, and has obvious anti-BCR-ABL + leukemia and breast cancer in the cellular level. The PRQ can significantly inhibit the growth of a BCR-ABL + leukemia cell line and an imatinib drug-resistant BCR-ABL + leukemia cell line, significantly inhibit the growth of breast cancer cells and induce ferroptosis of the breast cancer cells, and further researches find that the PRQ can degrade wild or mutant BCR-ABL proteins in a targeted manner. At the patient level, the PRQ is found to be capable of inhibiting the formation ability of primary cell colonies of wild-type or mutant patients with the BCR-ABL + leukemia, and at the animal level, the PRQ is found to have an obvious inhibiting effect on the progress of the BCR-ABL + leukemia.